Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $910000.0.

  • Ligand Pharmaceuticals' Interest Expenses rose 2280.7% to $910000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 6716.35%. This contributed to the annual value of $3.0 million for FY2024, which is 36295.73% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Interest Expenses of $910000.0 as of Q3 2025, which was up 2280.7% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Interest Expenses registered a high of $5.8 million during Q1 2021, and its lowest value of $1000.0 during Q3 2023.
  • Moreover, its 5-year median value for Interest Expenses was $789000.0 (2022), whereas its average is $1.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Interest Expenses tumbled by 9969.88% in 2023, and later surged by 7400000.0% in 2024.
  • Ligand Pharmaceuticals' Interest Expenses (Quarter) stood at $4.5 million in 2021, then crashed by 94.62% to $240000.0 in 2022, then plummeted by 45.42% to $131000.0 in 2023, then skyrocketed by 574.05% to $883000.0 in 2024, then increased by 3.06% to $910000.0 in 2025.
  • Its Interest Expenses was $910000.0 in Q3 2025, compared to $1.2 million in Q2 2025 and $867000.0 in Q1 2025.